CO6170341A2 - Formulacion de aerosol que contiene derivados de benzoxazin-3onas - Google Patents

Formulacion de aerosol que contiene derivados de benzoxazin-3onas

Info

Publication number
CO6170341A2
CO6170341A2 CO09028168A CO09028168A CO6170341A2 CO 6170341 A2 CO6170341 A2 CO 6170341A2 CO 09028168 A CO09028168 A CO 09028168A CO 09028168 A CO09028168 A CO 09028168A CO 6170341 A2 CO6170341 A2 CO 6170341A2
Authority
CO
Colombia
Prior art keywords
enantiomers
salts
4alkyl
possibly
alkyl
Prior art date
Application number
CO09028168A
Other languages
English (en)
Spanish (es)
Inventor
Kirsten Radau
Michael Aven
Silvia Weitzel
Robin Yannik Weitzel
Vanessa Sabrina Weitzel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6170341A2 publication Critical patent/CO6170341A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO09028168A 2006-08-18 2009-03-18 Formulacion de aerosol que contiene derivados de benzoxazin-3onas CO6170341A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119131 2006-08-18
EP07101129 2007-01-25

Publications (1)

Publication Number Publication Date
CO6170341A2 true CO6170341A2 (es) 2010-06-18

Family

ID=38521160

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09028168A CO6170341A2 (es) 2006-08-18 2009-03-18 Formulacion de aerosol que contiene derivados de benzoxazin-3onas

Country Status (18)

Country Link
US (2) US20080041369A1 (und)
EP (1) EP2054084A1 (und)
JP (1) JP2010501022A (und)
KR (1) KR20090057393A (und)
AR (1) AR062425A1 (und)
AU (1) AU2007285747A1 (und)
BR (1) BRPI0715761A2 (und)
CA (1) CA2660488A1 (und)
CO (1) CO6170341A2 (und)
IL (1) IL197025A0 (und)
MX (1) MX2009001759A (und)
NO (1) NO20090407L (und)
NZ (1) NZ575425A (und)
PE (1) PE20081319A1 (und)
SG (1) SG174058A1 (und)
TW (1) TW200817011A (und)
UY (1) UY30542A1 (und)
WO (1) WO2008020057A1 (und)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
AU2006281449B2 (en) * 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
EP2675439A2 (en) 2011-02-17 2013-12-25 Cipla Limited Combination of glycopyrrolate and a beta2 -agonist
EP3318247A1 (en) 2011-08-12 2018-05-09 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
CA2888428C (en) 2012-12-21 2021-07-13 Boehringer Ingelheim Vetmedica Gmbh Ciclesonide for the treatment of airway disease in horses
WO2014096116A1 (en) * 2012-12-21 2014-06-26 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical formulation comprising ciclesonide
CA2952701C (en) 2014-06-18 2023-09-19 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
US11701478B2 (en) 2015-10-09 2023-07-18 Boehringer Ingelheim International Gmbh Method for coating microstructured components
CN115811978B (zh) * 2020-06-23 2024-04-26 广州谷森制药有限公司 包含奥达特罗、噻托溴铵和布地奈德的药物组合物的制备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
DE102004019540A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
ES2523518T3 (es) * 2004-04-22 2014-11-26 Boehringer Ingelheim International Gmbh Nuevas combinaciones farmacológicas para el tratamiento de enfermedades de las vías respiratorias
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7528253B2 (en) * 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
PE20081319A1 (es) 2008-10-16
JP2010501022A (ja) 2010-01-14
SG174058A1 (en) 2011-09-29
US20080041369A1 (en) 2008-02-21
US20120058980A1 (en) 2012-03-08
NO20090407L (no) 2009-04-29
MX2009001759A (es) 2009-02-25
UY30542A1 (es) 2008-03-31
CA2660488A1 (en) 2008-02-21
AR062425A1 (es) 2008-11-05
WO2008020057A1 (de) 2008-02-21
NZ575425A (en) 2011-12-22
BRPI0715761A2 (pt) 2013-09-24
TW200817011A (en) 2008-04-16
IL197025A0 (en) 2009-11-18
AU2007285747A1 (en) 2008-02-21
EP2054084A1 (de) 2009-05-06
KR20090057393A (ko) 2009-06-05

Similar Documents

Publication Publication Date Title
CO6170341A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
CO6150123A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
AR058082A1 (es) Formulacion en aerosol para la inhalacion de beta- agonistas
AR049096A1 (es) Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas
NO20061833L (no) Aerosolformulgering for inhalering, inneholdende anticholinergt middel
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
AR124662A2 (es) Formulaciones inmunosupresoras
MX2012002011A (es) Composicion farmaceutica que contiene derivado de quinolina.
AR066505A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitogenos
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
JP2010501022A5 (und)
AR049650A1 (es) Derivados 5-aril-1h-pirrol[2,3-b]piridin-3-carboxamida o acido 5-aril-1h-pirrol[2,3-b]piridin-3-carboxilico
CO6351734A2 (es) Compuestos de amida utiles en terapia
AR094100A1 (es) DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS b2 ADRENERGICOS Y COMO ANTAGONISTAS MUSCARINICOS M3
BR112020008531A2 (pt) compostos antibacterianos
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
AR062477A1 (es) Formulacion aerosol para la inhalacion de beta - agonistas
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
AR075235A1 (es) Derivados de indol como agentes anticancer.
WO2008151746A3 (de) 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL
CO6150169A2 (es) Benzoxazinonas sustituidas enantiomericamente puras y procedimientos para su preparacion
AR059836A1 (es) Beta-agonistas enantiomericamente puros, y su uso como medicamentos
GB0617867D0 (en) Chemical compounds
AR078819A1 (es) Derivados de aminotiazol inhibidores de calicreina tisular humana klk1), composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias respiratorias, tales como asma, entre otras.
AR078818A1 (es) Derivados de azaindol

Legal Events

Date Code Title Description
FC Application refused